PURPOSE: To assess the efficacy of intraarterial @entity3303 on peri- and post-procedural @entity158 and on length of hospital stay in @entity157 ( @entity157 ) @entity1 undergoing chemoembolization. MATERIALS AND METHODS: Twenty-eight @entity1 (19M, 9F, age range 49-76) who underwent hepatic chemoembolization at our Institution between March 2000 and February 2002 were included in the study. Group A consisted of 14 @entity1 who received intraarterial @entity3303 immediately before and during chemoembolization, while in the 14 @entity1 of group B @entity3303 was substituted with saline solution. The doses of centrally acting narcotics ( @entity1340 ) administered periprocedurally and in the three days following the procedure were compared, as were the hospitalization times. Subjective @entity158 was measured using the visual analogue scale. Chemoembolizations were performed with an emulsion of @entity4831 , @entity900 and @entity1259 followed by embolizing material (gelfoam of Contour particles) in order to achieve complete blood flow stop in the proper hepatic artery. RESULTS: No side effects were noted that could be due to systemic administration of @entity3303 . All @entity1 experienced some degree of @entity887 . Periprocedural, day 1 and day 2 post chemoembolization dosages of @entity1340 were significantly lower in group A with respect to group B @entity1 . No group A @entity1 required analgesia on day 3. No statistical difference was observed in time persistence of @entity390 and @entity391 , fever and hospitalization time between the two @entity1 groups. CONCLUSIONS: Intraarterial administration of @entity3303 before and during chemoembolization is a safe and effective method for preventing or reducing peri- and post-procedural @entity158 and dosage of narcotic analgesics in @entity1 with @entity157 . Hospitalization times did not differ significantly between the two groups, probably because of the other components of @entity887 , such as fever, @entity390 and @entity391 .

@entity157 : effect of intraarterial @entity3303 in peri- and post-procedural XXXX and hospitalization.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1340 :: ('MESH:D014147', 'Chemical') :: ['tramadol'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1259 :: ('MESH:D015251', 'Chemical') :: ['epirubicin'] @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting'] @entity887 :: ('MESH:D004617', 'Disease') :: ['post-embolization syndrome'] @entity3303 :: ('MESH:D008012', 'Chemical') :: ['lidocaine'] @entity4831 :: ('MESH:D004998', 'Chemical') :: ['lipiodol'] @entity158 :: ('MESH:D010146', 'Disease') :: ['pain'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma']
@entity158 :: (MESH:D010146,Disease) :: ['pain']
